146P Dynamic folate receptor-α (FRα) expression in recurrent ovarian cancer patients undergoing secondary debulking surgery: A real-world analysis

FRα is a clinically actionable target in ovarian cancer, with mirvetuximab soravtansine approved in patients with high expression based on PS2 scoring. However, FRα expression may be heterogeneous and dynamic. Real-world data on FRα expression patterns and their clinical implications remain limited We evaluated temporal changes in FRα expression between primary and secondary debulking surgery (SDS).